ArticleTranslational breast cancer research : a journal focusing on translational research in breast cancer2023

Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer: a long-term safety and overall survival update from the randomised, double-blind, placebo-controlled, phase 3 trial.

Qingyuan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.